FibroGen announced a royalty monetization financing with NovaQuest Capital Management that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth. NovaQuest is a strategic...
Read Story
November 08, 2022, 07:45 AM
|
Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.The term loan facility provides for up to $125 million of term...
Read Story
September 01, 2022, 07:50 AM
|
Hansa Biopharma AB, (Hansa), a pioneer in enzyme technology for rare immunological conditions, has entered into an agreement with U.S.-based NovaQuest Capital Management, securing $70 million in non-dilutive financing."This transaction, which extends...
Read Story
|
Savara, a clinical stage biopharmaceutical company focused on rare respiratory diseases, entered into a term loan agreement of $26.5 million with Silicon Valley Bank to replace its existing credit facility with the bank. The new facility represents a...
Read Story
|
BioXcel Therapeutics, a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced strategic financing agreements with funds managed by...
Read Story
|
Xeris Biopharma Holdings entered into a senior secured term loan agreement with funds managed by Hayfin Capital Management to provide Xeris with up to a total of $150 million of capital.Under the terms of the debt facility, Xeris drew down $100...
Read Story
|
Ardelyx, a biopharmaceutical company, announced it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners."We are pleased to enter into this agreement with SLR for non-dilutive capital ahead of an...
Read Story
February 25, 2022, 08:03 AM
|
Amryt, a global, commercial-stage biopharmaceutical company secured $125 million of senior credit facilities from funds managed by the Credit Group of Ares Management Corporation. Amryt will use a portion of the proceeds to refinance its previous...
Read Story
February 23, 2022, 07:18 AM
|
Corium, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, closed on a $235 million term loan agreement with Hercules Capital. Corium will receive an initial...
Read Story
September 29, 2021, 07:32 AM
|